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Overexpression of the Cell Cycle Inhibitor p16INK4a
Promotes a Prothrombotic Phenotype Following Vascular
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Herbert C. Whinna, Frank C. Church
Objective—Age-associated cellular senescence is thought to promote vascular dysfunction. p16INK4a is a cell cycle
inhibitor that promotes senescence and is upregulated during normal aging. In this study, we examine the contribution
of p16INK4a overexpression to venous thrombosis.
Methods and Results—Mice overexpressing p16INK4a were studied with 4 different vascular injury models: (1) ferric
chloride (FeCl3) and (2) Rose Bengal to induce saphenous vein thrombus formation; (3) FeCl3 and vascular ligation to
examine thrombus resolution; and (4) lipopolysaccharide administration to initiate inflammation-induced vascular
dysfunction. p16INK4a transgenic mice had accelerated occlusion times (13.10.4 minutes) compared with normal
controls (19.71.1 minutes) in the FeCl3 model and 12.72.0 and 18.61.9 minutes, respectively in the Rose Bengal
model. Moreover, overexpression of p16INK4a delayed thrombus resolution compared with normal controls. In response
to lipopolysaccharide treatment, the p16INK4a transgenic mice showed enhanced thrombin generation in plasma-based
calibrated automated thrombography assays. Finally, bone marrow transplantation studies suggested increased p16INK4a
expression in hematopoietic cells contributes to thrombosis, demonstrating a role for p16INK4a expression in venous
thrombosis.
Conclusion—Venous thrombosis is augmented by overexpression of the cellular senescence protein p16INK4a. (Arterio-
scler Thromb Vasc Biol. 2011;31:827-833.)
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Aging is an important risk factor for developing cardio-vascular disease, and also the least understood.1,2 Ve-
nous thromboembolism (VTE) is characterized by the devel-
opment of thrombi in the deep veins of the legs; these thrombi
are prone to dislodging and embolizing to the lungs. This
condition accounts for 140 000 to 200 000 deaths each year in
the United States.3,4 The risk of developing VTE substantially
increases with age, and individuals over the age of 55 years
have an annual incidence 5 to 7 times higher than young
adults.5 Although VTE in the younger population is often
explained by mutations in hemostatic genes, mechanisms
behind the increased risk of VTE in the elderly are less well
understood.
Senescence is one cellular phenomenon known to be
associated with aging. Cellular senescence is a stress-induced
process that is controlled by cell cycle inhibitors and that
promotes an irreversible growth arrest.6–9 p16INK4a, a cell
cycle inhibitor that promotes senescence, binds to cyclin-
dependent kinases 4 and 6 to disrupt phosphorylation of the
retinoblastoma protein, causing a G1 cell cycle arrest.10
Expression of p16INK4a increases with age in many tissues
and is a biomarker of aging.11–14 Furthermore, p16INK4a
expression correlates with biomarkers of senescence, such as
senescence-associated -galactosidase expression, and ex-
pression is associated with gerontogenic activities, such as
smoking, physical inactivity, and ad libitum feeding in
humans or mice.11,14 In some tissues such as pancreatic
-cells, neural stem cells, and hematopoietic stem or progen-
itor cells, the age-induced increase in p16INK4a expression is
associated with reduced cellular proliferation coupled with an
impaired tissue response to injury.15–17 Additionally, senes-
cent cells are thought to contribute to aging pathology
through the production of cytokines (interleukin-6) that fur-
ther promote inflammation and cellular dysfunction.18
The contribution of senescence to disease in the venous
circulation and how it may be involved in age-related VTE or
a possible prothrombotic phenotype remain largely unchar-
acterized. The aim of this study was to ascertain whether
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overexpression of p16INK4a modified venous thrombus for-
mation in several well-defined animal models. Our results
demonstrate that p16INK4a overexpression augments vascular
occlusion and delayed thrombus resolution relative to wild-
type controls. Furthermore, p16INK4a transgenic mice display
enhanced thrombin generation, increased thrombin-
antithrombin, and increased plasminogen activator inhibitor-1
(PAI-1) levels when exposed to low-dose lipopolysaccharide
(LPS). Additionally, bone marrow transplantation between
wild-type and p16INK4a transgenic mice demonstrated a sub-
stantial contribution of hematopoietic cells to this phenotype.
Overall, these results show that expression of p16INK4a is
involved in promoting a prothrombotic environment in the
venous vasculature.
Methods
A detailed description of the methods is presented in the Supple-
mental Materials, available online at http://atvb.ahajournals.org.
Mice
All animal procedures were performed in accordance with protocols
approved by the Institutional Animal Care and Use Committee of
University of North Carolina–Chapel Hill. The bacterial artificial
chromosome transgenic mice overexpressing p16INK4a used in this
study have been described previously.15
Hemostasis Model
Hemostasis was assessed as previously described.19 Briefly, wild-
type and p16INK4a transgenic mice at 8 weeks of age were anesthe-
tized with 2.5% tribromoethanol (T48402, Sigma-Aldrich, St. Louis,
MO) at 0.1 mL/g body weight. The saphenous vein of anesthetized
mice was exposed and transected with a 23-gauge needle. Once
bleeding stopped, a longitudinal cut was made in the vessel, and the
blood was gently wiped away with Kimwipes (Kimberly-Clark,
Roswell, GA) until it clotted. The blood clot was disrupted using a
30-gauge needle, and the blood was gently wiped away. Clot
disruption was repeated every time hemostasis occurred, and each
hemostatic event was recorded using Chart software for 20 minutes.
FeCl3 Vascular Injury
The saphenous vein thrombosis model was performed as previously
described.19 Briefly, the saphenous veins of anesthetized mice were
exposed and dissected away from the saphenous artery. A
0.52-mm piece of filter paper was soaked in 2.5% (n4), 5%
(n5), or 10% (n4) FeCl3 (F7134, Sigma-Aldrich) and laid over
the saphenous vein for 3 minutes. The filter paper was then removed,
and the tissue was washed 3 times with warm saline. Blood flow was
monitored using a 20-MHz Doppler flow probe (Indus Instruments,
Webster, TX). Occlusion was defined as the absence of blood flow
for 1 minute. The time to flow restriction was defined as the time
after injury at first cessation of blood flow.
Rose Bengal Photochemical Vascular Injury
Photochemical injury was performed as previously described.20
Briefly, both right and left saphenous veins of anesthetized mice
were exposed. The left saphenous vein was catheterized using
catheters made in-house using pulled PE-10 tubing (Braintree
Scientific, Braintree, MA). Rose Bengal (R-3877, Sigma-Aldrich),
diluted to 30 mg/mL in normal saline, was infused through the
catheter at a dose of 75 mg/kg through a gastight syringe (Hamilton
Co, Reno, NV). Before infusion of Rose Bengal, a 1.75-mW green
light (540 nm) (Prizmatix, Southfield, MI) was directed 0.5 cm over
the injury site on the right saphenous vein. Light was applied to the
vessel until a stable thrombus (defined as the absence of blood flow
for 1 minute) was achieved.
Thrombus Resolution
We developed a new method to measure thrombus resolution using
the saphenous vein. Wild-type and p16INK4a transgenic mice (n3
per genotype at each time point) were subjected to 10% FeCl3 injury
to the saphenous vein. The tissue was then washed 3 times with
warm saline, a single ligature was placed upstream of the thrombus
using a 8-0 monofilament polypropylene suture to prevent emboli-
zation, and the leg was sutured closed. Mice were euthanized at
various time points, and the saphenous neurovascular bundle was
removed and fixed overnight in 4% paraformaldehyde and paraffin
embedded. Five-micrometer sections were cut and hematoxylin and
eosin (H&E) stained to visualize the presence of a thrombus under
light microscopy. Vessels were sectioned through, and those sections
showing the greatest area of occlusion were chosen for analysis.
Such sections typically occurred near the center of the injured vessel.
Images were analyzed using ImageJ software to calculate the
percentage of the vessel lumen that remained occluded by a
thrombus.
Low-Dose LPS Treatment
Wild-type and p16INK4a transgenic mice were treated with 2 mg/kg
intraperitoneal injection of LPS (L3012, Sigma-Aldrich). At various
times (1, 3, and 5 hours), the mice (n5 per genotype each time
point) were anesthetized, and 1 mL of blood was collected from the
inferior vena cava into 3.8% sodium citrate at a ratio of 1:9 using a
25-gauge needle. Whole blood was spun at 4000g for 15 minutes,
and the platelet-poor plasma was collected and stored at 80°C until
it was analyzed.
Bone Marrow Transplantation
This procedure was performed as described previously.21 Briefly,
mice were irradiated using a cesium-137 irradiator (JL Shepherd,
San Fernando, CA) with a total of 11 Gy (2 doses of 550 rad, with
a 4-hour rest) to abolish endogenous hematopoietic cells. Bone
marrow cells were isolated from donor mice,21 and 1107 cells were
injected (100 L) into the retroorbital sinus. Four weeks after
irradiation, recipient mice underwent FeCl3 injury to the saphenous
vein to determine vascular occlusion times. At termination, recipient
mouse bone marrow was genotyped to verify successful repopulation
of donor cells by polymerase chain reaction. Expression of p16INK4a
was compared with an interleukin-2 loading control.
Statistics
All statistical analyses were performed with GraphPad Prism. All
measurements are represented as the meanSEM. One-way
ANOVA or Student t test was performed where indicated. Values of
P0.05 were considered statistically significant.
Results
p16INK4a Transgenic and Wild-Type Mice Respond
Similarly in a Hemostasis Model
To determine the contribution of p16INK4a overexpression to
potential hemostatic defects, mice initially underwent a
model of saphenous vein hemostasis. No difference was
observed in the number of hemostatic clots formed over 20
minutes between transgenic mice (25.83.4) and wild-type
mice (25.82.1, Figure 1A) or in the average time to
hemostasis (33.53.7 and 36.62.6 seconds, respectively,
Figure 1B). Furthermore, no significant differences were
observed in body weight, venous blood flow velocity, plasma
prothrombin time, and complete blood count between the 2
groups of mice (Supplemental Table I). These results suggest
that there is no obvious physical or hematologic phenotype in
the p16INK4a transgenic mice at the ages studied.
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p16INK4a Transgenic Mice Display a
Prothrombotic Phenotype in an FeCl3
Injury Model
FeCl3 injury is a well-established mechanism for inducing
thrombus formation in vivo.22–24 We first demonstrated a
dose-dependent effect of FeCl3 on the occlusion time in the
saphenous vein, exposing wild-type mice to 2.5%, 5%, and
10% FeCl3 injuries to the saphenous vein (Figure 2A).
Wild-type and p16INK4a transgenic mice were then sub-
jected to FeCl3 (5%) injury to the saphenous vein. The
p16INK4a transgenic mice showed a significantly shorter time
to occlusion (13.10.4 minutes) compared with wild-type
mice (19.71.1 minute, Figure 2B). Furthermore, the time to
flow restriction was also measured. The p16INK4a transgenic
mice demonstrated shorter times to flow restriction
(6.40.91) compared with wild-type controls (8.70.54,
P0.05, data not shown). These results indicate that overex-
pression of p16INK4a results in a prothrombotic phenotype
following vascular injury.
p16INK4a Transgenic Mice Display a
Prothrombotic Phenotype in a Photochemical
Injury Model
The excitation of Rose Bengal to induce photochemical
injury is another well-established mechanism for inducing
thrombus formation in vivo.25–27 On photochemical injury to
the saphenous vein, p16INK4a transgenic mice displayed a
significantly shorter time to occlusion (12.72.0 minutes)
compared with wild-type mice (18.61.9 minutes, Figure 3).
These results suggest that the prothrombotic phenotype in
mice overexpressing p16INK4a can be recapitulated in other
vascular injury models.
p16INK4a Transgenic Mice Exhibit Delayed
Thrombus Resolution
Venous thrombosis is characterized by the presence of unre-
solved thrombi in the lower extremities. To study the effect of
Figure 1. Hemostatic parameters in saphenous vein hemostasis
model. Hemostatic measurements were compared between
wild-type and p16INK4a transgenic (Tg) mice following blunt
injury to the saphenous vein. A, The number of hemostatic clots
formed. B, The average time to stoppage of bleeding following
serial clot disruption over 30 minutes. Data are not statistically
significant.
Figure 2. Overexpression of p16INK4a decreases time to occlu-
sion in FeCl3 vascular injury model. A, Wild-type mice were sub-
jected to increasing doses of FeCl3 to the saphenous vein to
determine a dose-dependent effect on the occlusion time, as
described in Materials and Methods. *P0.01 versus 2.5%
FeCl3. B, Vascular occlusion times were compared between
wild-type and p16INK4a transgenic mice after 5% FeCl3 injury to
the saphenous vein. The occlusion time represents the amount
of time required to form an occlusive thrombus, as described in
Materials and Methods. *P0.01 versus wild-type control by the
Student t test.
Figure 3. p16INK4a transgenic (Tg) mice have decreased time
to occlusion in Rose Bengal photochemical vascular injury
model. Vascular occlusion times between wild-type and
p16INK4a transgenic mice were compared following saphenous
vein injury with 75 mg/kg Rose Bengal excited with 1.75 mW
green light at 540 nm. Occlusion times represent the amount of
time required to form an occlusive thrombus. *P0.05 versus
wild-type control by the Student t test.
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overexpressing p16INK4a on thrombus resolution, thrombi
formed post-FeCl3 injury in wild-type and p16
INK4a transgenic
mice were monitored over time. Mice were euthanized from 1
hour to 15 days post-FeCl3 injury and vascular ligation. No
significant differences in thrombus resolution were observed
until 7 days after vascular injury. By 10 days postinjury, all
wild-type mice exhibited complete thrombus resolution, whereas
p16INK4a transgenic mice maintained an average of 60% vessel
occlusion. p16INK4a transgenic mice required additional time
postinjury for thrombus resolution relative to wild-type controls
(Figure 4A). Representative images show little difference in
percentage of occlusion at 1 day (Figure 4B) between p16INK4a
transgenic and wild-type mice. Black staining represents FeCl3
trapped within the thrombus. At 10 days, we observed that
residual FeCl3 was mostly contained within inflammatory mac-
rophages and was present in the perivascular space of wild-type
mice. However, residual FeCl3 contained within macrophages
was still present in the intravascular space of p16INK4a transgenic
mice at 10 days (Figure 4B). These results demonstrate a defect
in thrombus resolution with p16INK4a overexpression.
p16INK4a Transgenic Mice Display Enhanced
Thrombin Generation in Response to LPS Challenge
Chronic inflammation and endothelial dysfunction have been
linked to enhanced thrombin generation and the risk of venous
thrombosis.28–30 LPS is known to activate the vascular endothe-
lium and promote the formation of spontaneous thrombi.31–34 To
study the effects of inflammation-induced coagulation, we ex-
posed p16INK4a transgenic and wild-type mice to low-dose LPS.
When analyzed by calibrated automated thrombography, plasma
from the p16INK4a transgenic mice showed a significantly shorter
lag time to initiation of thrombin generation and time to peak
amount of thrombin generated at all time points post–LPS
treatment (Table). The peak amount of thrombin generated was
significantly higher in p16INK4a transgenic mice 3 and 5 hours
after LPS treatment (Table). The observed differences in throm-
bin generation demonstrates p16INK4a transgenic mice are able to
generate more thrombin and have a prothrombotic phenotype
when challenged with LPS.
p16INK4a Expression in Hematopoietic Cells
Contributes to the Observed
Prothrombotic Phenotype
To determine the relative contribution of p16INK4a expression
in the hematopoietic cell compartment to the observed pro-
thrombotic phenotype, bone marrow transplants were per-
formed between transgenic and wild-type mice. Following
transplantation and recovery, mice were subjected to 10%
FeCl3 injury to the saphenous vein. Consistent with our
previous results (Figure 2B), transgenic mice receiving trans-
genic bone marrow had retained their significantly reduced
occlusion time (8.40.48 minutes) when compared with
Figure 4. p16INK4a transgenic mice display
defective thrombus resolution. A, Thrombus
resolution was measured over time after
10% FeCl3 injury to the saphenous vein and
stasis induced by ligation as described in
the Materials and Methods. *P0.05 versus
the respective wild-type control by the Stu-
dent t test. f, wild-type; Œ, p16INK4a trans-
genic. B, Representative histological images
were analyzed using ImageJ software to
determine the percentage of occlusion (plot-
ted in A). a, Wild-type at 1 day; b, p16
transgenic at 1 day; c, wild-type at 10 days;
d, p16 transgenic at 10 days.
Table. Thrombin Generation in Wild-Type vs p16INK4a Transgenic Mouse Plasma after LPS Treatment
Lag Time (minutes) Peak Height (nM) Time to Peak (minutes)
Time (hours) WT p16INK4a Tg WT p16INK4a Tg WT p16INK4a Tg
0 2.170.19 2.330.24 46.160.53 49.151.98 5.330.87 5.210.62
1 3.40.16 1.850.12* 45.449.45 44.211.3 6.190.27 4.520.14*
3 2.850.11 1.850.09* 36.440.43 51.260.63* 6.070.16 4.410.16*
5 2.010.17 2.510.19* 32.060.46 39.550.67* 5.180.23 5.520.11*
Thrombin generation in plasma from mice treated with 2 mg/kg LPS was measured using calibrated automated
thrombography, as described in the Supplemental Materials and Methods. Data represent experiments performed in
duplicate with 5 mice per group per time point. WT indicates wild-type; Tg, transgenic.
*P0.05.
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wild-type mice receiving wild-type bone marrow (13.00.79
minutes, Figure 5). Interestingly, transgenic mice receiving
wild-type bone marrow displayed occlusion times similar to
those of wild-type mice (12.81.3 minutes), whereas wild-
type mice receiving transgenic bone marrow displayed occlu-
sion times similar to those of transgenic mice (9.50.61
minutes, Figure 5). Polymerase chain reaction results con-
firmed successful reconstitution by donor bone marrow cells
(Supplemental Figure III). These results demonstrate that the
effects of p16INK4a overexpression are, at least in part,
mediated by hematopoietic cells.
Discussion
Senescence is a complex process that is thought to contribute
to cardiovascular pathologies associated with aging. Despite
several reviews describing prothrombotic changes in senes-
cent vascular endothelial cells,35,36 no studies have described
a venous thrombotic phenotype in mice overexpressing
senescence-promoting genes. In the current study, we exam-
ined parameters that define venous thrombotic potential in a
mouse model of premature senescence through transgenic
overexpression of the cell cycle inhibitor p16INK4a. As ex-
pected, the p16INK4a transgenic mouse exhibited increased
expression of p16INK4a mRNA by real-time polymerase chain
reaction analysis in all tissues tested. Mice overexpressing
p16INK4a exhibit normal basal hemostatic parameters as tested
by complete blood count, prothrombin time, and an in vivo
hemostasis model. This suggests that in the absence of
vascular injury, overexpression of p16INK4a has no overt
hemostatic consequences. However, on challenge in various
vascular injury models, the p16INK4a transgenic mice dis-
played an obvious prothrombotic response.
We have demonstrated a prothrombotic phenotype using 2
different vascular injury models. Exposure of the vessel to
FeCl3 is a type of biochemical injury that results in endothe-
lial denudation and exposure of the subendothelium follow-
ing lipid peroxidation.37 This type of oxidative damage
produces thrombi that are rich in platelets but also contain red
blood cells both encased in a dense fibrin meshwork, indi-
cating a role for soluble plasma factors driving thrombus
formation.38–40 Rose Bengal is a fluorescein-based chemical
that is excited to produce reactive oxygen species when
exposed to green light at 540 nm. This results in endothelial
activation, although there is very little denudation, and is
accompanied by rapid platelet adhesion. Thrombi in this
model are composed primarily of platelets and contain less
fibrin, implying that this process is mostly platelet driven.38
The observation that p16INK4a transgenic mice exhibit shorter
occlusion times in both of these models suggests that there is
likely a contribution by both soluble plasma factors and
circulating cells. The differences observed in the time to flow
restriction may reflect altered rates of thrombus growth
between wild-type and p16INK4a transgenic mice, which could
be indicative of the potential to produce larger thrombi.
In addition to more rapid rates of venous occlusion,
p16INK4a transgenic mice also display impaired thrombus
resolution. The percentage of occlusion appears to be corre-
lated with the sustaining of inflammatory infiltration. It is
possible that the inability to clear residual FeCl3 from the
intravascular space could be involved in further promoting
thrombus formation. The increased production of PAI-1
observed in p16INK4a transgenic mice could also partly
explain the thrombus resolution defect (Supplemental Figure
II). Evidence in the literature suggests increased circulating
PAI-1 could have a negative impact on wound healing and
fibrinolysis. Originally, Farrehi et al demonstrated enhanced
fibrinolysis in PAI-1-deficient mice.41 Eitzman et al found
that transgenic mice overexpressing PAI-1 have more severe
fibrosis following bleomycin-induced lung injury.42 Zaman et
al showed a profibrotic effect of PAI-1 overexpression in the
heart following myocardial infarction.43 Recently, McDonald
et al demonstrated that aged mice display impaired thrombus
resolution following stasis induced by inferior vena cava
ligation.44 In addition, they reported differences in various
plasma and venous endothelium-associated proteins between
aged and young wild-type mice.44 Although an exact mech-
anism to account for the observed thrombus resolution defect
in the aged mice is not yet known,44 it is possible that changes
in both the vessel wall and soluble plasma factors contribute,
which may also be true of p16INK4a overexpressing mice.
To better understand differences in thrombus formation
between p16INK4a transgenic and wild-type mice, coagulation
parameters in mouse plasma samples were analyzed by
calibrated automated thrombography after inducing endothe-
lial dysfunction with LPS. Plasma analysis by calibrated
automated thrombography is sensitive to changes in coagu-
lation factor levels45 and able to detect differences in throm-
bin generation parameters following a thrombotic event in
human patients.46 Our results show that p16INK4a transgenic
mice are able to initiate thrombin generation faster, achieve a
higher peak amount of thrombin, and peak at a faster rate than
wild-type controls. Therefore, p16INK4a transgenic mice ex-
hibit greater thrombin generation after LPS challenge com-
pared with wild-type controls. To complement these data,
p16INK4a transgenic mice also showed elevated plasma levels
of thrombin-antithrombin and PAI-1 following LPS chal-
lenge. These markers are commonly used to measure activa-
Figure 5. Vascular occlusion times are altered by bone marrow
transplantation. Vascular occlusion times were compared
between cohorts of bone marrow–transplanted mice following
injury of the saphenous vein with 10% FeCl3. Occlusion time
represents the amount of time required to form an occlusive
thrombus. *P0.05 versus wild-type control cohort; **P0.05
versus transgenic control cohort; #P0.08 versus wild-type
control cohort. Statistical relevance was determined by 1-way
ANOVA with the Tukey post hoc analysis.
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tion of coagulation (thrombin-antithrombin)33,47 and endothe-
lial activation (PAI-1).48,49 Yamamoto et al showed that aged
mice had elevated induction of PAI-1 compared with young
mice after LPS treatment, suggesting that PAI-1 is important
in endotoxin-induced thrombosis.31 Because PAI-1 is both a
marker of endothelial cell senescence and a potent fibrinoly-
sis inhibitor,50 it could also participate in the delayed throm-
bus resolution seen in p16INK4a transgenic mice.
To begin establishing a mechanism for the observed
differences between wild-type and p16INK4a transgenic mice,
bone marrow transplants were performed to determine the
contribution of hematopoietic cells to the prothrombotic
phenotype. We found that wild-type mice given p16INK4a
transgenic bone marrow had occlusion times very similar to
those of transgenic controls. Similarly, p16INK4a transgenic
mice given wild-type bone marrow had occlusion times very
similar to those of wild-type controls. These data show that
the prothrombotic phenotype observed in mice overexpress-
ing this gene is attributed to p16INK4a expression in hemato-
poietic cells.
A growing body of in vitro evidence suggests that senes-
cence in the vascular endothelium may also participate in the
transition to a procoagulant state during aging. Senescence in
the vascular endothelium is associated with an array of
phenotypic changes with pathological consequences.7,8 These
changes include upregulation of PAI-1, inflammatory cyto-
kines (including interleukin-1 and interleukin-6), matrix
metalloproteinases, and the downregulation of endothelial
nitric oxide synthase.35,36,51 Thus, a role for the endothelium
cannot be discounted and may warrant further investigation in
this model.
In contradistinction to the present data supporting a role for
p16INK4a in venous thrombosis, a differing role for the
expression of p16INK4a in arterial vascular diseases has been
suggested. Through genome-wide association studies, several
groups have found a link between single-nucleotide poly-
morphisms on chromosome 9p21.3 close to the p16INK4a
open-reading frame and several atherosclerotic diseases (cor-
onary artery disease, ischemic stroke, abdominal aortic aneu-
rysm).52 Liu et al have recently shown that individuals
harboring the single-nucleotide polymorphism genotypes as-
sociated with increased atherosclerotic risk exhibit decreased
expression of p16INK4a and other INK4/ARF transcripts.53
Individuals at increased risk appear to differ in the expression
and splicing of linear and circular forms of ANRIL, a long,
noncoding RNA emanating from the INK4a/ARF locus
thought to participate in INK4a/ARF expression.54 This ob-
servation suggests that decreased production of p16INK4a is
associated with an increased risk of atherosclerosis, likely
through limiting aberrant or excess proliferation of cellular
components of atheromatous plaques. This suggests that
expression of antiproliferative molecules at the INK4a/ARF
locus protects individuals from atherosclerosis.52,55 In accord
with this view, mice lacking p16INK4a have been shown to be
more prone to vessel occlusion in a carotid artery injury model.56
Our current data, combined with prior work in the venous
system,35,36 suggest the intriguing possibility that age-induced
p16INK4a expression and cellular senescence might play oppos-
ing roles with regard to thrombosis and atherosclerosis in the
venous and arterial systems, respectively.
Characterizing the link between age-related genetic
changes and age-related cardiovascular diseases, such as
venous thrombosis, is of paramount importance. Overexpres-
sion of proteins such as p16INK4a, which promote senescence
and vascular dysfunction, could be the key age-related
genetic change explaining cardiovascular maladies. Together,
our results demonstrate that p16INK4a overexpression and
cellular senescence contribute to a prothrombotic phenotype
and defective thrombus resolution. The results of this study
provide the foundation for research on the effects of vascular
senescence on venous thrombosis.
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10. Stein GH, Dulić V. Molecular mechanisms for the senescent cell cycle
arrest. J Investig Dermatol Symp Proc. 1998;3:14–18.
11. Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su
L, Sharpless NE. Ink4a/Arf expression is a biomarker of aging. J Clin
Invest. 2004;114:1299–1307.
12. Sharpless NE. Ink4a/Arf links senescence and aging. Exp Gerontol.
2004;39:1751–1759.
13. Dimri GP. The search for biomarkers of aging: next stop INK4a/ARF
locus. Sci Aging Knowledge Environ. 2004;2004:pe40.
14. Liu Y, Sanoff HK, Cho H, Burd CE, Torrice C, Ibrahim JG, Thomas NE,
Sharpless NE. Expression of p16(INK4a) in peripheral blood T-cells is a
biomarker of human aging. Aging Cell. 2009;8:439–448.




 http://ahajournals.org by on July 14, 2020
15. Krishnamurthy J, Ramsey MR, Ligon KL, Torrice C, Koh A,
Bonner-Weir S, Sharpless NE. p16INK4a induces an age-dependent
decline in islet regenerative potential. Nature. 2006;443:453–457.
16. Molofsky AV, Slutsky SG, Joseph NM, He S, Pardal R, Krishnamurthy
J, Sharpless NE, Morrison SJ. Increasing p16INK4a expression decreases
forebrain progenitors and neurogenesis during ageing. Nature. 2006;443:
448–452.
17. Janzen V, Forkert R, Fleming HE, Saito Y, Waring MT, Dombkowski
DM, Cheng T, DePinho RA, Sharpless NE, Scadden DT. Stem-cell
ageing modified by the cyclin-dependent kinase inhibitor p16INK4a.
Nature. 2006;443:421–426.
18. Campisi J, d’Adda di Fagagna F. Cellular senescence: when bad things
happen to good cells. Nat Rev Mol Cell Biol. 2007;8:729–740.
19. Buyue Y, Whinna HC, Sheehan JP. The heparin-binding exosite of factor
IXa is a critical regulator of plasma thrombin generation and venous
thrombosis. Blood. 2008;112:3234–3241.
20. Eitzman DT, Westrick RJ, Nabel EG, Ginsburg D. Plasminogen activator
inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood.
2000;95:577–580.
21. Pawlinski R, Wang J, Owens AP, Williams J, Antoniak S, Tencati M,
Luther T, Rowley JW, Low EN, Weyrich AS, Mackman N. Hemato-
poietic and nonhematopoietic cell tissue factor activates the coagulation
cascade in endotoxemic mice. Blood. 2010;116:806–814.
22. Wang X, Xu L. An optimized murine model of ferric chloride-induced
arterial thrombosis for thrombosis research. Thromb Res. 2005;115:
95–100.
23. Westrick RJ, Winn ME, Eitzman DT. Murine models of vascular
thrombosis (Eitzman series). Arterioscler Thromb Vasc Biol. 2007;27:
2079–2093.
24. Whinna HC. Overview of murine thrombosis models. Thromb Res. 2008;
122(suppl 1):S64–S69.
25. Jeske WP, Iqbal O, Fareed J, Kaiser B. A survey of venous thrombosis
models. Methods Mol Med. 2004;93:221–237.
26. Sachs UJH, Nieswandt B. In vivo thrombus formation in murine models.
Circ Res. 2007;100:979–991.
27. Rumbaut RE, Slaff DW, Burns AR. Microvascular thrombosis models in
venules and arterioles in vivo. Microcirculation. 2005;12:259–274.
28. Wakefield TW, Myers DD, Henke PK. Mechanisms of venous
thrombosis and resolution. Arterioscler Thromb Vasc Biol. 2008;28:
387–391.
29. Sattar N. Inflammation and endothelial dysfunction: intimate companions
in the pathogenesis of vascular disease? Clin Sci. 2004;106:443–445.
30. Schouten M, Wiersinga WJ, Levi M, van der Poll T. Inflammation,
endothelium, and coagulation in sepsis. J Leukoc Biol. 2008;83:536–545.
31. Yamamoto K, Shimokawa T, Yi H, Isobe K, Kojima T, Loskutoff DJ,
Saito H. Aging accelerates endotoxin-induced thrombosis: increased
responses of plasminogen activator inhibitor-1 and lipopolysaccharide
signaling with aging. Am J Pathol. 2002;161:1805–1814.
32. Wang X. Lipopolysaccharide augments venous and arterial thrombosis in
the mouse. Thromb Res. 2008;123:355–360.
33. Wang J, Manly D, Kirchhofer D, Pawlinski R, Mackman N. Levels of
microparticle tissue factor activity correlate with coagulation activation in
endotoxemic mice. J Thromb Haemost. 2009;7:1092–1098.
34. Yanada M, Kojima T, Ishiguro K, Nakayama Y, Yamamoto K, Mat-
sushita T, Kadomatsu K, Nishimura M, Muramatsu T, Saito H. Impact of
antithrombin deficiency in thrombogenesis: lipopolysaccharide and
stress-induced thrombus formation in heterozygous antithrombin-
deficient mice. Blood. 2002;99:2455–2458.
35. Erusalimsky JD, Kurz DJ. Cellular senescence in vivo: its relevance in
ageing and cardiovascular disease. Exp Gerontol. 2005;40:634–642.
36. Erusalimsky JD. Vascular endothelial senescence: from mechanisms to
pathophysiology. J Appl Physiol. 2009;106:326–332.
37. Tseng MT, Dozier A, Haribabu B, Graham UM. Transendothelial
migration of ferric ion in FeCl3 injured murine common carotid artery.
Thromb Res. 2006;118:275–280.
38. Mousa SA. In vivo models for the evaluation of antithrombotics and
thrombolytics. Methods Mol Biol. 2010;663:29–107.
39. Dubois C, Panicot-Dubois L, Merrill-Skoloff G, Furie B, Furie BC.
Glycoprotein VI-dependent and -independent pathways of thrombus for-
mation in vivo. Blood. 2006;107:3902–3906.
40. Woollard KJ, Sturgeon S, Chin-Dusting JPF, Salem HH, Jackson SP.
Erythrocyte hemolysis and hemoglobin oxidation promote ferric chloride-
induced vascular injury. J Biol Chem. 2009;284:13110–13118.
41. Farrehi PM, Ozaki CK, Carmeliet P, Fay WP. Regulation of arterial
thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation.
1998;97:1002–1008.
42. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, Simon
RH. Bleomycin-induced pulmonary fibrosis in transgenic mice that either
lack or overexpress the murine plasminogen activator inhibitor-1 gene.
J Clin Invest. 1996;97:232–237.
43. Zaman AKMT, French CJ, Schneider DJ, Sobel BE. A profibrotic effect
of plasminogen activator inhibitor type-1 (PAI-1) in the heart. Exp Biol
Med (Maywood). 2009;234:246–254.
44. McDonald AP, Meier TR, Hawley AE, Thibert JN, Farris DM, Wrobleski
SK, Henke PH, Wakefield TW, Myers DD. Aging is associated with
impaired thrombus resolution in a mouse model of stasis induced
thrombosis. Thromb Res. 2010;125:72–78.
45. Machlus KR, Colby EA, Wu JR, Koch GG, Key NS, Wolberg AS. Effects
of tissue factor, thrombomodulin and elevated clotting factor levels on
thrombin generation in the calibrated automated thrombogram. Thromb
Haemost. 2009;102:936–944.
46. ten Cate-Hoek AJ, Dielis AWJH, Spronk HMH, van Oerle R, Hamulyak
K, Prins MH, ten Cate H. Thrombin generation in patients after acute
deep-vein thrombosis. Thromb Haemost. 2008;100:240–245.
47. Hron G, Kollars M, Weber H, Sagaster V, Quehenberger P, Eichinger S,
Kyrle PA, Weltermann A. Tissue factor-positive microparticles: cellular
origin and association with coagulation activation in patients with colo-
rectal cancer. Thromb Haemost. 2007;97:119–123.
48. Ruan QR, Zhang WJ, Hufnagl P, Kaun C, Binder BR, Wojta J. Ani-
sodamine counteracts lipopolysaccharide-induced tissue factor and plas-
minogen activator inhibitor-1 expression in human endothelial cells:
contribution of the NF-B pathway. J Vasc Res. 2001;38:13–19.
49. Zhang WJ, Wojta J, Binder BR. Notoginsenoside R1 counteracts
endotoxin-induced activation of endothelial cells in vitro and endotoxin-
induced lethality in mice in vivo. Arterioscler Thromb Vasc Biol. 1997;
17:465–474.
50. Gramling MW, Church FC. Plasminogen activator inhibitor-1 is an
aggregate response factor with pleiotropic effects on cell signaling in
vascular disease and the tumor microenvironment. Thromb Res. 2010;
125:377–381. http://www.ncbi.nlm.nih.gov/pubmed/20079523. Accessed
March 12, 2010.
51. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, Wang T, Gregg D,
Ramaswami P, Pippen AM, Annex BH, Dong C, Taylor DA. Aging,
progenitor cell exhaustion, and atherosclerosis. Circulation. 2003;108:
457–463.
52. Jarinova O, Stewart AFR, Roberts R, Wells G, Lau P, Naing T, Buerki C,
McLean BW, Cook RC, Parker JS, McPherson R. Functional analysis of
the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler
Thromb Vasc Biol. 2009;29:1671–1677.
53. Liu Y, Sanoff HK, Cho H, Burd CE, Torrice C, Mohlke KL, Ibrahim JG,
Thromas NE, Sharpless NE. INK4/ARF transcript expression is asso-
ciated with chromosome 9p21 variants linked to atherosclerosis. PLoS
One. 2009;4:e5027.
54. Burd CE, Jeck WR, Liu Y, Sanoff HK, Wang Z, Sharpless NE.
Expression of linear and novel circular forms of an INK4/ARF-associated
non-coding RNA correlates with atherosclerosis risk. PLoS Genet. 2010;
6:e1001233.
55. Visel A, Zhu Y, May D, Afzal V, Gong E, Attanasio C, Blow MJ, Cohen
JC, Rubin EM, Pennacchio LA. Targeted deletion of the 9p21 non-coding
coronary artery disease risk interval in mice. Nature. 2010;464:409–412.
56. Gizard F, Amant C, Barbier O, Bellosta S, Robillard R, Percevault F,
Sevestre H, Krimpenfort P, Corsini A, Rochette J, Glineur C, Fruchart JC,
Torpier G, Staels B. PPAR inhibits vascular smooth muscle cell prolif-
eration underlying intimal hyperplasia by inducing the tumor suppressor
p16INK4a. J Clin Invest. 2005;115:3228–3238.




 http://ahajournals.org by on July 14, 2020
